Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.88+0.08 (+0.30%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Viking Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Viking Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $586.17M, up 163.5% year over year. For fiscal 2025 it was $344.96M, up 239.4% from the year before. Over ten years it grew 47.7% a year on average. The highest annual figure on record is $344.96M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $344.96M | +239.4% |
| FY2024 | Dec 31, 2024 | $101.64M | +59.3% |
| FY2023 | Dec 31, 2023 | $63.81M | +17.6% |
| FY2022 | Dec 31, 2022 | $54.23M | +20.6% |
| FY2021 | Dec 31, 2021 | $44.98M | +40.9% |
| FY2020 | Dec 31, 2020 | $31.93M | +35.5% |
| FY2019 | Dec 31, 2019 | $23.56M | +23.7% |
| FY2018 | Dec 31, 2018 | $19.04M | +38.6% |
| FY2017 | Dec 31, 2017 | $13.74M | +52.7% |
| FY2016 | Dec 31, 2016 | $9.00M | +29.2% |
| FY2015 | Dec 31, 2015 | $6.97M | -68.7% |
| FY2014 | Dec 31, 2014 | $22.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $166.80M | +85.4% |
| Q2 FY2026 | Jun 30, 2026 | $115.75M | +92.4% |
| Q1 FY2026 | Mar 31, 2026 | $150.15M | +262.8% |
| Q4 FY2025 | Dec 31, 2025 | $153.46M | +395.2% |
| Q3 FY2025 | Sep 30, 2025 | $89.95M | +294.8% |
| Q2 FY2025 | Jun 30, 2025 | $60.15M | +153.1% |
| Q1 FY2025 | Mar 31, 2025 | $41.39M | +71.7% |
| Q4 FY2024 | Dec 31, 2024 | $30.99M | +51.1% |
| Q3 FY2024 | Sep 30, 2024 | $22.79M | +24.0% |
| Q2 FY2024 | Jun 30, 2024 | $23.77M | +70.8% |
| Q1 FY2024 | Mar 31, 2024 | $24.10M | +119.0% |
| Q4 FY2023 | Dec 31, 2023 | $20.50M | +26.7% |
| Q3 FY2023 | Sep 30, 2023 | $18.38M | +53.7% |
| Q2 FY2023 | Jun 30, 2023 | $13.92M | +2.8% |
| Q1 FY2023 | Mar 31, 2023 | $11.01M | -12.3% |
| Q4 FY2022 | Dec 31, 2022 | $16.18M | +64.3% |
| Q3 FY2022 | Sep 30, 2022 | $11.96M | +10.8% |
| Q2 FY2022 | Jun 30, 2022 | $13.54M | +5.8% |
| Q1 FY2022 | Mar 31, 2022 | $12.56M | +8.8% |
| Q4 FY2021 | Dec 31, 2021 | $9.85M | +8.8% |
| Q3 FY2021 | Sep 30, 2021 | $10.80M | +51.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.80M | +64.6% |
| Q1 FY2021 | Mar 31, 2021 | $11.54M | +44.4% |
| Q4 FY2020 | Dec 31, 2020 | $9.05M | +40.3% |
| Q3 FY2020 | Sep 30, 2020 | $7.12M | +34.8% |
| Q2 FY2020 | Jun 30, 2020 | $7.78M | +6.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.99M | +77.6% |
| Q4 FY2019 | Dec 31, 2019 | $6.45M | +26.8% |
| Q3 FY2019 | Sep 30, 2019 | $5.28M | -7.2% |
| Q2 FY2019 | Jun 30, 2019 | $7.33M | +40.5% |
| Q1 FY2019 | Mar 31, 2019 | $4.50M | +47.7% |
| Q4 FY2018 | Dec 31, 2018 | $5.09M | +67.8% |
| Q3 FY2018 | Sep 30, 2018 | $5.69M | +64.1% |
| Q2 FY2018 | Jun 30, 2018 | $5.22M | +40.5% |
| Q1 FY2018 | Mar 31, 2018 | $3.04M | -13.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.03M | +14.6% |
| Q3 FY2017 | Sep 30, 2017 | $3.47M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.72M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.65M | – |
See a number that looks wrong?